# US 2025/0164486 A1 · Method of assessing risk of pml

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164486 A1
- Document ID: US20250164486A1
- Status: Published application
- Kind: A1
- Application number: 18/809,113
- Filed: 2024-08-19
- Published: 2025-05-22
- Earliest claimed: 2011-05-31
- Assignees: Biogen MA Inc.
- Applicants: Biogen MA Inc.
- Inventors: Gary Lewis Bloomgren; Carmen Bozic; Sophia Lee; Meena Subramanyam; Tatiana Plavina
- Web page: https://patentgrep.com/patent/US20250164486A1

## CPC

- G01N 33/56983: {Viruses}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 2710/22011: Polyomaviridae, e.g. polyoma, SV40, JC
- G01N 2333/025: Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N 2800/28: Neurological disorders
- G01N 2800/2814: Dementia; Cognitive disorders
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).

## Claims

### Claim 1

A method of evaluating the level of anti-JCV antibody in a sample, comprising:
(a) forming a first reaction mixture comprising a first aliquot of sample and a substrate on which is disposed HPVLP; and
(b) detecting the level of anti-JCV antibody bound to said substrate on which is disposed HPVLP by detecting a labeled detection reagent bound to anti-JCV antibody bound to said substrate;
wherein one or both of the following are met: (i) 20 ngs to 60 ngs of HPVP are disposed on said substrate and (ii) the ratio of sample to substrate is between 1:50 and 1:30,
thereby evaluating the level of anti-JCV antibody in a sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein said sample, e.g., serum, is diluted, e.g., by about 100 fold, in, e.g., buffer, prior to contact with said substrate.

### Claim 3 (depends on 1)

The method of claim 1, wherein detection is with an enzyme labeled antibody, e.g., an enzyme labeled IgG, e.g., an HRP labeled IgG; optionally wherein the detection reagent is added at a concentration of at least 0.01 μg/mL, 0.02 μg/mL, 0.03 μg/mL, 0.04 μg/mL, 0.05 μg/mL, 0.06 μg/mL, or 0.08 μg/ml.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, further comprising
(c) forming a second reaction mixture containing a second aliquot of sample and solution-phase HPVLP, and detecting the level of unbound anti-JCV antibody in said second reaction mixture, such as by detecting anti-JCV antibody capable of binding with a substrate on which is disposed HPVLP; and optionally (d) forming a third reaction mixture containing a third aliquot under conditions where anti-JCV antibodies in the sample are not bound by HPVLP or other antigen, and detecting the level of unbound anti-JCV antibody in the third reaction mixture, such as by detecting anti-JCV antibody capable of binding with a substrate on which is disposed HPVLP,
to provide a value for interference.

### Claim 6 (depends on 5)

The method of claim 5, comprising comparing the detected level in said second reaction mixture with the detected level in said third reaction mixture.

### Claim 7 (depends on 6)

The method of claim 6, wherein said comparing comprises determining the level to which the presence of HPVLP in the second reaction mixture inhibits the level of unbound anti-JCV antibody in said second reaction mixture as compared with the level of unbound antibody in said third reaction mixture.

### Claim 8 (depends on 7)

The method of claim 7, wherein said inhibition is less than 45% and, optionally, said sample is classified as negative.

### Claim 9 (depends on 7)

The method of claim 7, wherein said inhibition is greater than or equal to 45% and said sample is classified as positive.

### Claim 10 (depends on 1, 5)

The method of claim 5, wherein said method is performed responsive to the level of anti-JCV antibodies detected in step b of claim 1, e.g., the nOD value is <0.2 and <0.4 and proceeding to steps c and d.

### Claim 11 (depends on 5)

The method of claim 5, wherein said sample, e.g., serum, is diluted, e.g., by about 100 fold, in, e.g., buffer, prior to forming said second reaction mixture and/or third reaction mixture.

### Claim 12

(canceled)

### Claim 13 (depends on 5)

The method of claim 5, wherein detection for one or both of said second and third reaction mixtures is with an enzyme labeled antibody, e.g., an enzyme labeled IgG, e.g., an HRP labeled IgG; optionally wherein detection for one or both of said second and third reaction mixture is with an HRP labeled IgG added at a concentration of at least 0.01 μg/mL, 0.02 μg/mL, 0.03 μg/mL, 0.04 μg/mL, 0.05 μg/mL, 0.06 μg/mL, or 0.08 μg/ml.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, further comprising evaluating a standard, e.g., a cut off calibrator, having, e.g., a score of about 1, in step b

### Claim 16 (depends on 1)

The method of claim 1, further comprising evaluating a standard, e.g., positive control, having, e.g., a score of about 1.3, in step b.

### Claim 17 (depends on 1)

The method of claim 1, further comprising evaluating a standard, e.g., negative control, having, e.g., a score of about 0.1, in step b.

### Claim 18 (depends on 1)

A kit comprising a substrate of claim 1; optionally wherein said substrate is provided on a multiwell plate, e.g., a 96 well plate.

### Claim 19

(canceled)

### Claim 20 (depends on 18)

The kit of claim 18, further comprising one or more or all of the following: HPVLP in solution; a JCV cut-off calibrator, an anti-JCV antibody positive control and a JCV negative control, which are samples of human sera; and reagents for detecting a complex containing anti-JCV antibodies bound to JCV antigen.

### Claim 21 (depends on 20)

The kit of claim 20, wherein the detection reagents are one or more of TMB (tetramethylbenzidine), a wash buffer, and a stop reagent.

### Claim 22

A method of evaluating a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML), the method comprising:
determining a JC Virus (JCV) antibody titer expressed as nOD, index or other unit, or other characteristics such as affinity or avidity expressed as percent inhibition in the anti-JCV antibody confirmation assay in a biological sample from the patient, wherein
if the titer or/and percent inhibition, or function of both values is determined to be above or below a pre-determined level, the patient is determined to be at a lower risk of developing PML, and wherein if the titer or/and percent inhibition, or function of both values is determined to be above or below a pre-determined level, the patient is determined to be at an intermediate risk of developing PML, and wherein if the titer or/and percent inhibition, or a function of both values is determined to be at or above the pre-determined level the patient is determined to be at a higher risk of developing PML, and further provided that either
(i) determining the anti-JCV antibody titer or percent inhibition in a sample of the patient comprises removing a biological sample from the patient's body or analyzing a sample from the patient, or
(ii) if the patient is determined to be at a lower risk of developing PML, administering a therapy to the patient.

### Claim 23 (depends on 22)

The method of claim 22, wherein the patient is determined to be at a lower risk of developing PML, and the patient is administered an anti-VLA-4 therapy.

### Claim 24 (depends on 22)

The method of claim 22, wherein the patient is determined to have a lower risk of PML if,
(i) the anti-JCV antibody titer as indicated by index value or nOD is determined to be <0.5, or
(ii) the anti-JCV antibody titer as indicated by index value or nOD is determined to be >0.5 and <3.0, and the percent inhibition is determined to be less than or equal to 70%.

### Claim 25 (depends on 22)

The method of claim 22, wherein the patient is determined to have an intermediate risk of PML if,
(i) the anti-JCV antibody titer as indicated by index value or nOD is determined to be >0.5 and <1.5, and
(ii) the percent inhibition value is determined to be >70%.

### Claim 26 (depends on 22)

The method of claim 22, wherein the patient is determined to have a higher risk of PML if,
(i) the anti-JCV antibody titer as indicated by index value or nOD is determined to be >3 and the percent inhibition value is determined to be >70%, or
(ii) the patient showed an increase in index, nOD or titer by 2-fold from a previous test.

### Claim 27 (depends on 26)

The method of claim 26, wherein percent inhibition of anti-JCV antibodies is measured by:
(i) contacting a biological sample from the subject with highly purified VP1 particles (HPVLPs) in a solution under conditions suitable for binding of an anti-JCV antibody in the sample to an HPVLP;
(ii) separating the JCV antibodies bound to HPVLP from the solution to create a secondary sample;
(iii) contacting the secondary sample with HPVLP under the same conditions as (i); and
(iv) detecting the level of anti-JCV antibody binding to HPVLP in the secondary sample.

### Claim 28 (depends on 22)

The method of claim 22, wherein the anti-JCV antibody titer is measured by an assay comprising:
(i) contacting the biological sample with HPVLPs under conditions suitable for binding of an anti-JCV antibody in the sample to an HPVLP;
(ii) detecting the level of anti-JCV antibody binding in the sample to HPVLPs; and
(iii) correlating the detected level with a reference set, wherein the reference set is selected to indicate a false negative rate not greater than 3%.

### Claim 29

(canceled)

### Claim 30 (depends on 28)

The method of claim 28, wherein the assay indicates that the biological sample does not contain JCV antibodies, and further comprising:
(iv) contacting a portion of the biological sample from the subject with HPVLP in a solution prior to step (i) and wherein the HPVLP of step (i) is attached to a solid substrate, thereby providing a secondary sample;
(v) contacting the secondary sample with HPVLP under the same conditions as (i);
(vi) detecting the level of anti-JCV antibody binding to HPVLP in the secondary sample; and
(vii) comparing the detected level of anti-JCV antibody in the secondary sample to the level of binding in the biological sample when incubated with the solution without HPVLP, wherein a decrease in the detected level in the sample pre-incubated with HPVLP compared to the solution-incubated sample indicates that the sample is positive for an anti-JCV antibody and no change in the detected level indicates that there is no anti-JCV antibody present in the sample.

### Claim 31 (depends on 28)

The method of claim 28, wherein the assay indicates that the biological sample contains JCV antibodies, and the patient is determined to be at higher risk for PML.

### Claim 32 (depends on 30)

The method of claim 30, wherein the assay indicates that the biological sample contains JCV antibodies, and the patient is determined to be at higher risk for PML.

### Claim 33 (depends on 30)

The method of claim 30, wherein the patient is determined to have a lower risk of PML if,
(i) the anti-JCV antibody titer as indicated by index value or nOD is determined to be <0.5, or
(ii) the anti-JCV antibody titer as indicated by index value or nOD is determined to be >0.5 and <3.0, and the percent inhibition is determined to be less than or equal to 70%.

### Claim 34 (depends on 30)

The method of claim 30, wherein the patient is determined to have a higher risk of PML if,
(i) the anti-JCV antibody titer as indicated by index value or nOD is determined to be >3 and the percent inhibition value is determined to be >70%, or
(ii) the patient showed an increase in index, nOD or titer by 2-fold from a previous test.

### Claim 35 (depends on 30)

The method of claim 30, wherein the assay indicates that the biological sample does not contain JCV antibodies, and the patient is determined to be at lower risk for PML.

### Claim 36 (depends on 22)

The method of claim 22, wherein the anti-JCV antibody titer or percent inhibition is retested at 6 months or 12 month intervals.

### Claim 37

(canceled)

### Claim 38 (depends on 36)

The method of claim 36, wherein a 2 fold or greater increase in anti-JCV antibody titer indicates an increased risk of developing PML.

### Claim 39 (depends on 22)

The method of claim 22, wherein the evaluation occurs prior to administration of an anti-VLA-4 therapy, or wherein the evaluation occurs after the patient has begun an anti-VLA-4 therapy.

### Claim 40

(canceled)

### Claim 41 (depends on 22)

The method of claim 22, wherein the patient is determined to be at a lower risk of PML and the patient is administered an anti-VLA-4 therapy or wherein the patient is determined to be at a higher risk of PML and the patient is administered an anti-VLA-4 therapy.

### Claim 42

(canceled)

### Claim 43 (depends on 22)

The method of claim 22, wherein the anti-VLA-4 therapy is natalizumab.

### Claim 44 (depends on 37)

The method of claim 37, wherein the patient is determined to have an increased risk for PML, and the patient further stops receiving the anti-VLA-4 therapy.

### Claim 45 (depends on 22)

The method of claim 22, wherein the patient is determined to be at a higher risk for PML, and the patient is administered an alternative to an anti-VLA-4 therapy, e.g., an interferon, glatiramer acetate or a corticosteroid.

### Claim 46 (depends on 44)

The method of claim 44, wherein the patient is monitored at regular intervals for a decrease in anti-JCV antibody titer or a decrease in percent inhibition of JCV antibodies, wherein a decrease in anti-JCV antibody titer or a decrease in percent inhibition of JCV antibodies indicates that the patient has a lowered risk of developing PML.

### Claim 47 (depends on 44)

The method of claim 44, wherein the JCV titer or percent inhibition of JCV antibodies is determined to be decreased below a pre-determined level, and the patient's anti-VLA-4 therapy is reinstated.

### Claim at position 48

48-85. (canceled)
